Duchenne Muscular Dystrophy Treatment Market is estimated to bring in US$ 10,664.5 million revenue by 2026
Duchenne Muscular Dystrophy (DMD) is a type of muscular disorder due to which most of the people are unable to walk at a very early stage and the affected muscles look larger due to the fat content. The symptoms include muscle weakness, difficulty in walking and breathing and intellectual disability. Although, the treatment to control and reduce the signs and symptoms is available, yet there is no cure for DMD. Key players in the market are also trying to spread awareness about DMD along with the investment in finding a treatment for the disease. Meanwhile, human clinical trials are also underway to find out effective therapy.
Request to Sample of Report @ https://www.persistencemarketresearch.com/samples/12475
Increasing Investment in Research and Development to find a Treatment for DMD to Drive the Market Growth
Various pharmaceutical companies and organizations are increasingly investing in the research and development activities to come up with an effective treatment for duchenne muscular dystrophy. Meanwhile, there is an ongoing research on gene therapy, exon skipping drugs, and stem cell therapy to treat duchenne muscular dystrophy in a better way. Current pharmacological interventions for duchenne muscular dystrophy include approaches to mitigate downstream and secondary pathological mechanisms and solutions targeting primary defect. Patients with DMD are not able to produce a protein known as dystrophin. Hence, a variety of new medications are being developed to replace dystrophin. Moreover, new therapies aim to repair muscle damage caused due to the absence of dystrophin. However, delay in diagnosis and the high cost of treatment and drugs are some of the factors restricting the growth of the market.
Global Duchenne Muscular Dystrophy Market- Segment-Wise Analysis
The global duchenne muscular dystrophy market is segmented into therapy, distribution channel, product type, and region. The product type is further segmented into corticosteroids, NSAIDs, and other products. Among these, corticosteroids are likely to witness the highest growth during the forecast period. By the end of 2026, corticosteroids are estimated to bring in more than US$ 9,000 million revenue.
Based on the distribution channel, the global duchenne muscular dystrophy market segmentation includes online pharmacies, retail pharmacies, and hospital pharmacies. Hospitals pharmacies are expected to be the largest distributors in the duchenne muscular dystrophy market. Hospital pharmacies are anticipated to exceed US$ 6,000 million revenue towards the end of 2026.
On the basis of therapy, the market segmentation includes Exon Skipping Approach, Mutation Suppression, and other therapies. Mutation suppression therapy is expected to witness strong growth throughout the forecast period. By the end of 2026, mutation suppression therapy is estimated to bring in more than US$ 6,400 million revenue.
Europe is expected to be the dominating region in the global duchenne muscular dystrophy market during the forecast period. Owing to the high rate of people suffering from duchenne muscular dystrophy, Europe is witnessing the growth in adoption of treatment for muscular dystrophy. Also, various treatments are approved or under review to treat duchenne muscular dystrophy in Europe. This is also one of the reasons for the growth of the market in Europe.
Request Report for TOC @ https://www.persistencemarketresearch.com/methodology/12475
Sarepta Therapeutics, Inc., Santhera Pharmaceuticals, PTC Therapeutics, Summit Therapeutics plc, FibroGen, Inc., and ITALFARMACO S.p.A., are some of the leading players in the global duchenne muscular dystrophy market.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Duchenne Muscular Dystrophy Treatment Market is estimated to bring in US$ 10,664.5 million revenue by 2026 here
News-ID: 1138242 • Views: 469
More Releases from Persistence Market Research Pvt.Ltd.
Dental Restoration Market Present Scenario and the Growth Prospects 2017 - 2025
The term dental restoration covers an integrated management of oral health and restoring the oral health to a functional and esthetic state. The American Dental Association has not considered restorative dentist as a separate specialty though the dentists are able to perform man of these procedures without any additional course or certification. The dental restoration procedures depend on how difficult the procedure is and what the professional feels comfortable with.
Mobile Air Transfer Systems Market Trends and Key Developments 2017 - 2025
Mobile air transfer system is the system used in hospitals and other medical centers that helps to reduce patient handling injury. The system provides patients with simple and comfortable transfer experience along with significantly reducing the cumulative handling effect of thousands of pounds of patients’ weight while routine transfers. To ensure the safety of hundreds of millions of people suffering from health care associated infections and abnormalities mobile air transfer
Orthopedic Veterinary Implants Market is projected to reach US$ 3,500 Mn by 2026
Arthritis is a common disorder which has been recently seen spreading its roots dogs. At present, this diseases is treated with the help of orthopedic veterinary implants. The global orthopedic veterinary implants market has witnessed a substantial surge in the last couple years owing to the rise in pet adoption and their orthopedic surgeries. Majority of the population, especially in the developed regions, own pets such as cats or dogs.
Prepackaged Medical Kits and Trays Market is anticipated to Register a CAGR of 8 …
There has been a Herculean shift in the healthcare industry towards a reformed model and significant rise in investments worldwide is intended to improve various facilities and services across the healthcare industry. The concept of value-based pricing of pharmaceuticals has gained momentum in the last few years and a majority of the OECD countries have adopted this model. This shift has been a crucial component for the revenue growth of
More Releases for Duchenne
Duchenne Muscular Dystrophy (DMD) Drugs Market Report
As per the research conducted by GME, the Duchenne Muscular Dystrophy (DMD) Drugs Market will grow with a CAGR value of 41.3 percent by 2026. The global market for Duchenne muscular dystrophy is foreseen to grow due to accelerated research and development activities, expanded patient awareness for effective treatments, and the launch of new medications Moreover, the disease's increasing prominence is likely to drive the global duchenne muscular dystrophy market
Global Duchenne Muscular Dystrophy Therapeutics Market Productions, Statistics 2 …
Qyresearchreports include new market research report "Global Duchenne Muscular Dystrophy Therapeutics Market Size, Status and Forecast 2022" to its huge collection of research reports. The general market for Duchenne Muscular Dystrophy Therapeutics has been analysed on various points of view that are practically present in the scenario, and have affected the market situation to the large extent. The report also presents exceptional experience and data identified with global Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Duchenne Muscular Dystrophy - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2017, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape. Duchenne muscular dystrophy is a condition which causes muscle weakness. DMD is an X-linked disorder.
Duchenne Muscular Dystrophy (DMD) Treatment Market - Global Industry Insights, T …
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused due to alteration in gene sequence coding for dystrophin proterin, which is present the muscle. It is a rare muscle disease which majorly affects males. The symptoms includes intellectual disability, muscle weakness and, difficulty in walking and breathing. Congestive heart failure, mental impairment, pneumonia or respiratory failure are some of the
Duchenne Muscular Dystrophy - Pipeline Review, H2 Pharmaceutical Research Report …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Duchenne Muscular Dystrophy - Pipeline Review, H2 2017”. Duchenne muscular dystrophy is a condition which causes muscle weakness. DMD is an X-linked disorder. The gene for DMD is present on the X chromosome. Request For Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1305512 It codes for a protein named dystrophin. Dystrophin is essential for providing structural support inside muscle cells.
Duchenne Muscular Dystrophy - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Duchenne Muscular Dystrophy - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1 2017, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape. Duchenne muscular dystrophy is a condition which causes muscle weakness. DMD is an X-linked disorder.